Search

Your search keyword '"Kultursay, Hakan"' showing total 119 results

Search Constraints

Start Over You searched for: Author "Kultursay, Hakan" Remove constraint Author: "Kultursay, Hakan"
119 results on '"Kultursay, Hakan"'

Search Results

1. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

3. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

4. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

5. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

6. Takotsubo syndrome after treatment with non-cardiotoxic chemotherapy agents

8. Is there a gender gap in secondary prevention of coronary artery disease in Turkey?

15. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

16. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

17. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

18. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

22. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

23. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

24. Serum Endocan Levels Predict Angiographic No-Reflow Phenomenon in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Intervention.

25. 33 Questions about Triglycerides and Cardiovascular Effects: Expert Answers

34. Repolarization characteristics and incidence of Torsades de Pointes in patients with acquired complete atrioventricular block

35. Pseudonormalization: clinical, electrocardiographic, echocardiographic, and angiographic characteristics

46. Pulmonary arterial hypertension and pregnancy.

48. Miyokart Enfarktüsü Boyutsal Değerlendirme Ölçeği (MIDAS) Türkçe sürümünün psikometrik özellikleri.

49. Benefits of statin treatment in cardiac syndrome-X1.

50. Serum paraoxonase 1 activity and oxidative markers of LDL in patients with cardiac syndrome X

Catalog

Books, media, physical & digital resources